Epigenetische Wirkstoffentwicklung: Molekül Identifizierung und Optimierung, sowie Target Validierung (Z02)

点击翻译按钮获取中文摘要

The development of high-affinity inhibitors with potential application in clinical therapy involves a structured process of identifying target proteins and lead structures for inhibitory compounds. Such leads are then optimised in iterative rounds of chemical modification, structural analysis and functional assays. The Z02 core facility provides the CRC with the know-how and equipment to scale-up protein production, identify and validate suitable target proteins, obtain three-dimensional structures, find candidate compounds and optimise leads for ligand screening and protein crystallisation.